Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Activation and Characterization of Procarboxypeptidase B from Human Plasma

Cite this: Biochemistry 1995, 34, 17, 5811–5816
Publication Date (Print):May 2, 1995
https://doi.org/10.1021/bi00017a012
    ACS Legacy Archive

    Article Views

    193

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Note: In lieu of an abstract, this is the article's first page.

    Free first page

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 116 publications.

    1. Nis Halland, Jörg Czech, Werngard Czechtizky, Andreas Evers, Markus Follmann, Markus Kohlmann, Herman A. Schreuder, and Christopher Kallus . Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa). Journal of Medicinal Chemistry 2016, 59 (20) , 9567-9573. https://doi.org/10.1021/acs.jmedchem.6b01276
    2. Nis Halland, Mark Brönstrup, Jörg Czech, Werngard Czechtizky, Andreas Evers, Markus Follmann, Markus Kohlmann, Matthias Schiell, Michael Kurz, Herman A. Schreuder, and Christopher Kallus . Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin. Journal of Medicinal Chemistry 2015, 58 (11) , 4839-4844. https://doi.org/10.1021/jm501840b
    3. Zuzana Valnickova,, Trine Christensen,, Peter Skottrup,, Ida B. Thøgersen,, Peter Højrup, and, Jan J. Enghild. Post-translational Modifications of Human Thrombin-Activatable Fibrinolysis Inhibitor (TAFI):  Evidence for a Large Shift in the Isoelectric Point and Reduced Solubility upon Activation. Biochemistry 2006, 45 (5) , 1525-1535. https://doi.org/10.1021/bi051956v
    4. Hongmin Zhen, Junlan Liu, Ke Xiong, Lingyan Zheng, Yumeng Hu, Mengmeng Li, Wen Jin. Engineering a carboxypeptidase from Aspergillus oryzae M30011 to improve the terminal-specific enzymatic hydrolysis of aromatic amino acids. Process Biochemistry 2023, 126 , 186-199. https://doi.org/10.1016/j.procbio.2023.01.001
    5. Aaron J. Cowieson, Laerke T. Haahr, Lars K. Skov. Starch- and Protein-Degrading Enzymes in Non-Ruminant Animal Production. 2022, 89-102. https://doi.org/10.1079/9781789241563.0006
    6. Hongmin Zhen, Junlan Liu, Ke Xiong, Lingyan Zheng, Yumeng Hu, Mengmeng Li, Wen Jin. Engineering a Carboxypeptidase from Aspergillus Oryzae M30011 to Improve the Terminal Specific Enzymatic Hydrolysis of Aromatic Amino Acids. SSRN Electronic Journal 2022, 59 https://doi.org/10.2139/ssrn.4180256
    7. Edem Gavor, Yeu Khai Choong, Nikhil Kumar Tulsian, Digant Nayak, Fakhriedzwan Idris, Hariharan Sivaraman, Donald Heng Rong Ting, Alonso Sylvie, Yu Keung Mok, R Manjunatha Kini, J Sivaraman. Structure of Aedes aegypti procarboxypeptidase B1 and its binding with Dengue virus for controlling infection. Life Science Alliance 2022, 5 (1) , e202101211. https://doi.org/10.26508/lsa.202101211
    8. Lise Boon, Estefania Ugarte-Berzal, Jennifer Vandooren, Ghislain Opdenakker. Protease propeptide structures, mechanisms of activation, and functions. Critical Reviews in Biochemistry and Molecular Biology 2020, 55 (2) , 111-165. https://doi.org/10.1080/10409238.2020.1742090
    9. T. Urano, F.J. Castellino, Y. Suzuki. Regulation of plasminogen activation on cell surfaces and fibrin. Journal of Thrombosis and Haemostasis 2018, 16 (8) , 1487-1497. https://doi.org/10.1111/jth.14157
    10. Toshimasa Itoh, Nobuko Yoshimoto, Yoshinari Hirano, Keiko Yamamoto. Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group. Bioorganic & Medicinal Chemistry Letters 2018, 28 (13) , 2256-2260. https://doi.org/10.1016/j.bmcl.2018.05.042
    11. Stefan Loroch, Katharina Trabold, Stepan Gambaryan, Cora Reiß, Kathrin Schwierczek, Ingrid Fleming, Albert Sickmann, Wolfgang Behnisch, Barbara Zieger, René P. Zahedi, Ulrich Walter, Kerstin Jurk. Alterations of the platelet proteome in type I Glanzmann thrombasthenia caused by different homozygous delG frameshift mutations in ITGA2B. Thrombosis and Haemostasis 2017, 117 (03) , 556-569. https://doi.org/10.1160/TH16-07-0515
    12. Chengliang Wu, Alan Stafford, James Fredenburgh, Jeffrey Weitz, Ann Gils, Paul Declerck, Paul Kim. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Thrombosis and Haemostasis 2017, 117 (08) , 1509-1517. https://doi.org/10.1160/TH17-01-0054
    13. X. Zhou, S.D. Weeks, P. Ameloot, N. Callewaert, S.V. Strelkov, P.J. Declerck. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity. Journal of Thrombosis and Haemostasis 2016, 14 (8) , 1629-1638. https://doi.org/10.1111/jth.13381
    14. T. Plug, J.A. Marquart, P.F. Marx, J.C.M. Meijers. Selective modulation of thrombin‐activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin‐thrombomodulin complex using TAFI‐derived peptides. Journal of Thrombosis and Haemostasis 2015, 13 (11) , 2093-2101. https://doi.org/10.1111/jth.13133
    15. Yutaka Masuda, Jun Yazawa, Yuuka Makino, Kimihiko Takada. PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells. Biological & Pharmaceutical Bulletin 2015, 38 (10) , 1529-1535. https://doi.org/10.1248/bpb.b15-00295
    16. Naourez Ktari, Hayet Ben Khaled, Imen Lassoued, Sofiane Ghorbel, Moncef Nasri. Isolation and Characteristics of Carboxypeptidase B from Zebra Blenny ( Salaria basilisca ) Viscera. Journal of Aquatic Food Product Technology 2014, 23 (3) , 208-220. https://doi.org/10.1080/10498850.2012.708388
    17. Qiang Zhang, Thomas J. D. Jørgensen, Peter E. Nielsen, Niels Erik Møllegaard, . A Phosphorylation Tag for Uranyl Mediated Protein Purification and Photo Assisted Tag Removal. PLoS ONE 2014, 9 (3) , e91138. https://doi.org/10.1371/journal.pone.0091138
    18. Abbasali Raz, Navid Dinparast Djadid, Sedigheh Zakeri, . Molecular Characterization of the Carboxypeptidase B1 of Anopheles stephensi and Its Evaluation as a Target for Transmission-Blocking Vaccines. Infection and Immunity 2013, 81 (6) , 2206-2216. https://doi.org/10.1128/IAI.01331-12
    19. Dirk F. Hendriks. Carboxypeptidase U. 2013, 1321-1324. https://doi.org/10.1016/B978-0-12-382219-2.00296-9
    20. Francesc X. Avilés, Josep Vendrell. Carboxypeptidase B. 2013, 1324-1329. https://doi.org/10.1016/B978-0-12-382219-2.00297-0
    21. Josep Vendrell, Francesc X. Avilés, Alex Bayés. Insect Gut Carboxypeptidase 3. 2013, 1370-1375. https://doi.org/10.1016/B978-0-12-382219-2.00307-0
    22. Yutaka Masuda, Dan Saotome, Kimihiko Takada, Katsuyoshi Sugimoto, Tomoyuki Sasaki, Hidemi Ishii. Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability. Thrombosis and Haemostasis 2012, 108 (07) , 74-85. https://doi.org/10.1160/TH12-02-0101
    23. David S. Waugh. An overview of enzymatic reagents for the removal of affinity tags. Protein Expression and Purification 2011, 80 (2) , 283-293. https://doi.org/10.1016/j.pep.2011.08.005
    24. Jonathan H. Foley, Paul F. Cook, Michael E. Nesheim. Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites. Journal of Biological Chemistry 2011, 286 (22) , 19280-19286. https://doi.org/10.1074/jbc.M110.215061
    25. Ellen Vercauteren, Jan Emmerechts, Miet Peeters, Marc F. Hoylaerts, Paul J. Declerck, Ann Gils. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 2011, 117 (17) , 4615-4622. https://doi.org/10.1182/blood-2010-08-303677
    26. Zuzana Valnickova, Morten Thaysen-Andersen, Peter Højrup, Trine Christensen, Kristian Sanggaard, Torsten Kristensen, Jan Enghild. Biochemical Characterization of Bovine Plasma Thrombin-Activatable Fibrinolysis Inhibitor (TAFI). 2011, 11-36. https://doi.org/10.1201/b13131-3
    27. Niraj Mishra, Ellen Vercauteren, Jan Develter, Riet Bammens, Paul J. Declerck, Ann Gils. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thrombosis and Haemostasis 2011, 106 (07) , 90-101. https://doi.org/10.1160/TH10-08-0546
    28. Zuzana Valnickova, Laura Sanglas, Joan L. Arolas, Steen V. Petersen, Christine Schar, Daniel Otzen, Francesc X. Aviles, F. Xavier Gomis-Rüth, Jan J. Enghild. Flexibility of the Thrombin-activatable Fibrinolysis Inhibitor Pro-domain Enables Productive Binding of Protein Substrates. Journal of Biological Chemistry 2010, 285 (49) , 38243-38250. https://doi.org/10.1074/jbc.M110.150342
    29. S.L. SCHADINGER, J.H.H. LIN, M. GARAND, M.B. BOFFA. Secretion and antifibrinolytic function of thrombin‐activatable fibrinolysis inhibitor from human platelets. Journal of Thrombosis and Haemostasis 2010, 8 (11) , 2523-2529. https://doi.org/10.1111/j.1538-7836.2010.04024.x
    30. Bengur Taskiran, Sibel Guldiken, Ahmet M. Demir, Tulay K. Okman, Ender Arikan, Burhan Turgut, Ayse A. Tugrul. Effect of obesity on TAFI in postmenopausal period. Obesity Research & Clinical Practice 2010, 4 (4) , e271-e276. https://doi.org/10.1016/j.orcp.2010.05.001
    31. J.L. WILLEMSE, E. HEYLEN, M.E. NESHEIM, D.F. HENDRIKS. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?. Journal of Thrombosis and Haemostasis 2009, 7 (12) , 1962-1971. https://doi.org/10.1111/j.1538-7836.2009.03596.x
    32. Zuzana Valnickova, Morten Thaysen-Andersen, Peter Højrup, Trine Christensen, Kristian W Sanggaard, Torsten Kristensen, Jan J Enghild. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI). BMC Biochemistry 2009, 10 (1) https://doi.org/10.1186/1471-2091-10-13
    33. Maday Alonso‐del‐Rivero, Sebastian A. Trejo, Mónica Rodríguez de la Vega, Yamile González, Silvia Bronsoms, Francesc Canals, Julieta Delfín, Joaquin Diaz, Francesc X. Aviles, María A. Chávez. A novel metallocarboxypeptidase‐like enzyme from the marine annelid Sabellastarte magnifica – a step into the invertebrate world of proteases. The FEBS Journal 2009, 276 (17) , 4875-4890. https://doi.org/10.1111/j.1742-4658.2009.07187.x
    34. Stacey L. Mueller-Ortiz, Dachun Wang, John E. Morales, Li Li, Jui-Yoa Chang, Rick A. Wetsel. Targeted Disruption of the Gene Encoding the Murine Small Subunit of Carboxypeptidase N (CPN1) Causes Susceptibility to C5a Anaphylatoxin-Mediated Shock. The Journal of Immunology 2009, 182 (10) , 6533-6539. https://doi.org/10.4049/jimmunol.0804207
    35. Chengliang Wu, Paul Y. Kim, Reg Manuel, Marian Seto, Marc Whitlow, Mariko Nagashima, John Morser, Ann Gils, Paul Declerck, Michael E. Nesheim. The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex. Journal of Biological Chemistry 2009, 284 (11) , 7059-7067. https://doi.org/10.1074/jbc.M804745200
    36. D.A. TREGOUET, R. SCHNABEL, M.C. ALESSI, T. GODEFROY, P.J. DECLERCK, V. NICAUD, T. MUNZEL, C. BICKEL, H.J. RUPPRECHT, E. LUBOS, T. ZELLER, I. JUHAN-VAGUE, S. BLANKENBERG, L. TIRET, P.E. MORANGE. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis 2009, 7 (1) , 49-57. https://doi.org/10.1111/j.1538-7836.2008.03221.x
    37. Michelle M Martínez-Montemayor, Gretchen M Hill, Nancy E Raney, Valencia D Rilington, Robert J Tempelman, Jane E Link, Christopher P Wilkinson, Antonio M Ramos, Catherine W Ernst. Gene expression profiling in hepatic tissue of newly weaned pigs fed pharmacological zinc and phytase supplemented diets. BMC Genomics 2008, 9 (1) https://doi.org/10.1186/1471-2164-9-421
    38. . Binding of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) to Plasminogen May Play a Role in the Fibrinolytic Pathway. Bulletin of the Korean Chemical Society 2008, 2209-2214. https://doi.org/10.5012/bkcs.2008.29.11.2209
    39. K. HILLMAYER, R. VANCRAENENBROECK, M. DE MAEYER, G. COMPERNOLLE, P.J. DECLERCK, A. GILS. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis 2008, 6 (11) , 1892-1899. https://doi.org/10.1111/j.1538-7836.2008.03130.x
    40. J.B. WALKER, T.M. BINETTE, M. MACKOVA, G.R. LAMBKIN, L. MITCHELL, L. BAJZAR. Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity. Journal of Thrombosis and Haemostasis 2008, 6 (5) , 848-855. https://doi.org/10.1111/j.1538-7836.2008.02912.x
    41. Jonathan H. Foley, Paula Kim, Michael E. Nesheim. Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis. Journal of Biological Chemistry 2008, 283 (14) , 8863-8867. https://doi.org/10.1074/jbc.M800127200
    42. Michael B. Boffa, Deborah Maret, Jeffrey D. Hamill, Nazareth Bastajian, Paul Crainich, Nancy S. Jenny, Zhonghua Tang, Elizabeth M. Macy, Russell P. Tracy, Rendrik F. Franco, Michael E. Nesheim, Marlys L. Koschinsky. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood 2008, 111 (1) , 183-189. https://doi.org/10.1182/blood-2007-03-078543
    43. Tanya M. Binette, Fletcher B. Taylor, Glenn Peer, Laszlo Bajzar. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007, 110 (9) , 3168-3175. https://doi.org/10.1182/blood-2007-03-078824
    44. Michael B. Boffa, Marlys L. Koschinsky. Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clinical Biochemistry 2007, 40 (7) , 431-442. https://doi.org/10.1016/j.clinbiochem.2006.10.020
    45. N.J. MUTCH, L. THOMAS, N.R. MOORE, K.M. LISIAK, N.A. BOOTH. TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. Journal of Thrombosis and Haemostasis 2007, 5 (4) , 812-817. https://doi.org/10.1111/j.1538-7836.2007.02430.x
    46. Toshihiko Nishimura, Timothy Myles, Adrian M. Piliposky, Peter N. Kao, Gerald J. Berry, Lawrence L. K. Leung. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007, 109 (5) , 1992-1997. https://doi.org/10.1182/blood-2006-03-012567
    47. Manuel Mansur, Liliam Martínez, Mariela Pérez, Maday Alonso-del-Rivero, Isvaloy Márquez, Yanay Proenza, Laura Varas, Francesc X. Avilés. Expression, purification and characterization of porcine pancreatic Carboxypeptidase B from Pichia pastoris for the conversion of recombinant human insulin. Enzyme and Microbial Technology 2007, 40 (3) , 476-480. https://doi.org/10.1016/j.enzmictec.2006.07.024
    48. Gabriela Niemirowicz, Fabiola Parussini, Fernán Agüero, Juan J. Cazzulo. Two metallocarboxypeptidases from the protozoan Trypanosoma cruzi belong to the M32 family, found so far only in prokaryotes. Biochemical Journal 2007, 401 (2) , 399-410. https://doi.org/10.1042/BJ20060973
    49. Lloyd Fricker. Carboxypeptidase U. 2007, 1-5. https://doi.org/10.1016/B978-008055232-3.60565-3
    50. Corinne Frère, David-Alexandre Tregouet, Pierre-Emmanuel Morange, Noémie Saut, Dinar Kouassi, Irène Juhan-Vague, Laurence Tiret, Marie-Christine Alessi. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 2006, 108 (5) , 1562-1568. https://doi.org/10.1182/blood-2006-01-008094
    51. D. EATON. Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). Journal of Thrombosis and Haemostasis 2006, 4 (1) , 260-261. https://doi.org/10.1111/j.1538-7836.2005.01669.x
    52. Pauline F. Marx, Joost C.M. Meijers. TAFI: regulating the cross talk between coagulation and fibrinolysis TAFI: Regulierung der Wechselwirkung zwischen Gerinnung und Fibrinolyse. LaboratoriumsMedizin 2005, 29 (6) , 412-420. https://doi.org/10.1515/JLM.2005.056
    53. Rosemarijn Renckens, Joris J. T. H. Roelofs, Simone A. J. ter Horst, Cornelis van ′t Veer, Stefan R. Havik, Sandrine Florquin, Gerry T. M. Wagenaar, Joost C. M. Meijers, Tom van der Poll. Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice. The Journal of Immunology 2005, 175 (10) , 6764-6771. https://doi.org/10.4049/jimmunol.175.10.6764
    54. Tsukasa Mori, Ikuei Hiraka, Youichi Kurata, Hiroko Kawachi, Osamu Kishida, Kinya Nishimura. Genetic basis of phenotypic plasticity for predator-induced morphological defenses in anuran tadpole, Rana pirica, using cDNA subtraction and microarray analysis. Biochemical and Biophysical Research Communications 2005, 330 (4) , 1138-1145. https://doi.org/10.1016/j.bbrc.2005.03.091
    55. C. Lavazec, S. Bonnet, I. Thiery, B. Boisson, C. Bourgouin. cpbAg1 encodes an active carboxypeptidase B expressed in the midgut of Anopheles gambiae. Insect Molecular Biology 2005, 14 (2) , 163-174. https://doi.org/10.1111/j.1365-2583.2004.00541.x
    56. Corinne Frère, Pierre Emmanuel Morange, Noémie Saut, David Alexandre Tregouet, Mariana Grosley, Jérôme Beltran, Irène Juhan-Vague, Marie-Christine Alessi. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thrombosis and Haemostasis 2005, 94 (08) , 373-379. https://doi.org/10.1160/TH04-08-0497
    57. D. Maret, M.B. Boffa, D.F. Brien, M.E. Nesheim, M.L. Koschinsky. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis 2004, 2 (11) , 1969-1979. https://doi.org/10.1111/j.1538-7836.2004.00971.x
    58. John B. Walker, Laszlo Bajzar. The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable Fibrinolysis Inhibitor Is Masked by Its Instability. Journal of Biological Chemistry 2004, 279 (27) , 27896-27904. https://doi.org/10.1074/jbc.M401027200
    59. Laszlo Bajzar, Nidhi Jain, Ping Wang, John B. Walker. Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis. Critical Care Medicine 2004, 32 (Supplement) , S320-S324. https://doi.org/10.1097/01.CCM.0000126361.00450.B1
    60. A. Reijerkerk, J.C.M. Meijers, S.R. Havik, B.N. Bouma, E.E. Voest, M.F.B.G. Gebbink. Tumor growth and metastasis are not affected in thrombin‐activatable fibrinolysis inhibitor‐deficient mice. Journal of Thrombosis and Haemostasis 2004, 2 (5) , 769-779. https://doi.org/10.1111/j.1538-7836.2004.00682.x
    61. David P. Bown, John A. Gatehouse. Characterization of a digestive carboxypeptidase from the insect pest corn earworm ( Helicoverpa armigera ) with novel specificity towards C‐terminal glutamate residues. European Journal of Biochemistry 2004, 271 (10) , 2000-2011. https://doi.org/10.1111/j.1432-1033.2004.04113.x
    62. Mark Schneider, Michael Nesheim. A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis. Journal of Biological Chemistry 2004, 279 (14) , 13333-13339. https://doi.org/10.1074/jbc.M313164200
    63. Mark Schneider, Nicole Brufatto, Erin Neill, Michael Nesheim. Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin. Journal of Biological Chemistry 2004, 279 (14) , 13340-13345. https://doi.org/10.1074/jbc.M313211200
    64. Josep Vendrell, Francesc X Aviles, Lloyd D Fricker. Metallocarboxypeptidases. 2004https://doi.org/10.1002/0470028637.met033
    65. Josep Vendrell, Francesc X Aviles, Lloyd D Fricker. Metallocarboxypeptidases. 2004https://doi.org/10.1002/9781119951438.eibc0499
    66. Pauline F. Marx, Stefan R. Havik, J. Arnoud Marquart, Bonno N. Bouma, Joost C.M. Meijers. Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry 2004, 279 (8) , 6620-6628. https://doi.org/10.1074/jbc.M307337200
    67. Dirk F. Hendriks. Carboxypeptidase U. 2004, 825-828. https://doi.org/10.1016/B978-0-12-079611-3.50250-0
    68. Kirstin W Matthews, Stacey L Mueller-Ortiz, Rick A Wetsel. Carboxypeptidase N: a pleiotropic regulator of inflammation. Molecular Immunology 2004, 40 (11) , 785-793. https://doi.org/10.1016/j.molimm.2003.10.002
    69. Bonno N Bouma, Joost C.M Meijers. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Seminars in Hematology 2004, 41 , 13-19. https://doi.org/10.1053/j.seminhematol.2003.11.004
    70. P.N. Walsh. Roles of factor XI, platelets and tissue factor-initiated blood coagulation. Journal of Thrombosis and Haemostasis 2003, 1 (10) , 2081-2086. https://doi.org/10.1046/j.1538-7836.2003.00460.x
    71. Michael Nesheim. Thrombin and Fibrinolysis. Chest 2003, 124 (3) , 33S-39S. https://doi.org/10.1378/chest.124.3_suppl.33S
    72. Shi-Shan Mao, Dennis Colussi, Carolyn M Bailey, Michele Bosserman, Christine Burlein, Stephen J Gardell, Steven S Carroll. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. Analytical Biochemistry 2003, 319 (1) , 159-170. https://doi.org/10.1016/S0003-2697(03)00252-5
    73. Lei Zhao, Brad Buckman, Marian Seto, John Morser, Mariko Nagashima. Mutations in the Substrate Binding Site of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) Alter Its Substrate Specificity. Journal of Biological Chemistry 2003, 278 (34) , 32359-32366. https://doi.org/10.1074/jbc.M300803200
    74. B.N. Bouma, J.C. M. Meijers. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Journal of Thrombosis and Haemostasis 2003, 1 (7) , 1566-1574. https://doi.org/10.1046/j.1538-7836.2003.00329.x
    75. John B. Walker, Bernadette Hughes, Ian James, Peter Haddock, Cornelis Kluft, Laszlo Bajzar. Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro. Journal of Biological Chemistry 2003, 278 (11) , 8913-8921. https://doi.org/10.1074/jbc.M205006200
    76. Michael B. Boffa, Jeffrey D. Hamill, Deborah Maret, Darryl Brown, Michelle L. Scott, Michael E. Nesheim, Marlys L. Koschinsky. Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. Journal of Biological Chemistry 2003, 278 (11) , 9250-9257. https://doi.org/10.1074/jbc.M209588200
    77. M. Schneider, M. Nesheim. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. Journal of Thrombosis and Haemostasis 2003, 1 (1) , 147-154. https://doi.org/10.1046/j.1538-7836.2003.00028.x
    78. Carmen M. Swaisgood, Detlef Schmitt, Dan Eaton, Edward F. Plow. In vivo regulation of plasminogen function by plasma carboxypeptidase B. Journal of Clinical Investigation 2002, 110 (9) , 1275-1282. https://doi.org/10.1172/JCI0215082
    79. Michael B. Boffa, Jeffrey D. Hamill, Nazareth Bastajian, Rebecca Dillon, Michael E. Nesheim, Marlys L. Koschinsky. A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry 2002, 277 (28) , 25329-25336. https://doi.org/10.1074/jbc.M203688200
    80. I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegård, E. Hawe, J. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries. Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22 (5) , 867-873. https://doi.org/10.1161/01.ATV.0000015445.22243.F4
    81. Hazar Shadid, Salim Aziz, Sarfraz Ahmad, Jawed Fareed, Debra Hoppensteadt, Harry Messmore, William Wehrmacher, Mahmut Tobu, Omer Iqbal. Antithrombotic agents in the treatment of severe sepsis. Expert Opinion on Emerging Drugs 2002, 7 (1) , 111-139. https://doi.org/10.1517/14728214.7.1.111
    82. Mark Schneider, Mariko Nagashima, Sabine Knappe, Lei Zhao, John Morser, Michael Nesheim. Amino Acid Residues in the P6-P′3 Region of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Do Not Determine the Thrombomodulin Dependence of TAFI Activation. Journal of Biological Chemistry 2002, 277 (12) , 9944-9951. https://doi.org/10.1074/jbc.M111685200
    83. Mark Schneider, Michael Boffa, Ronald Stewart, Mona Rahman, Marlys Koschinsky, Michael Nesheim. Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme. Journal of Biological Chemistry 2002, 277 (2) , 1021-1030. https://doi.org/10.1074/jbc.M104444200
    84. ML Koschinsky, MB Boffa, ME Nesheim, B Zinman, AJG Hanley, SB Harris, H Cao, RA Hegele. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin‐activable fibrinolysis inhibitor (TAFI) with blood pressure. Clinical Genetics 2001, 60 (5) , 345-349. https://doi.org/10.1034/j.1399-0004.2001.600504.x
    85. D.C. Rijken, D.V. Sakharov. Basic Principles in Thrombolysis: Regulatory Role of Plasminogen. Thrombosis Research 2001, 103 , S41-S49. https://doi.org/10.1016/S0049-3848(01)00296-1
    86. MICHAEL NESHEIM, JOHN WALKER, WEI WANG, MICHAEL BOFFA, ANTON HORREVOETS, LASZLO BAJZAR. Modulation of Fibrin Cofactor Activity in Plasminogen Activation. Annals of the New York Academy of Sciences 2001, 936 (1) , 247-260. https://doi.org/10.1111/j.1749-6632.2001.tb03513.x
    87. Katinka Schatteman, Filip Goossens, Judith Leurs, Robert Verkerk, Simon Scharpé, Jan J. Michiels, Dirk Hendriks. arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis. Clinical and Applied Thrombosis/Hemostasis 2001, 7 (2) , 93-101. https://doi.org/10.1177/107602960100700203
    88. Bonno N. Bouma, Pauline F. Marx, Laurent O. Mosnier, Joost C.M. Meijers. Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U). Thrombosis Research 2001, 101 (5) , 329-354. https://doi.org/10.1016/S0049-3848(00)00411-4
    89. Laszlo Bajzar. Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20 (12) , 2511-2518. https://doi.org/10.1161/01.ATV.20.12.2511
    90. C.J. Refino, L. DeGuzman, D. Schmitt, R. Smyth, S. Jeet, M.T. Lipari, D. Eaton, S. Bunting. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis. Fibrinolysis and Proteolysis 2000, 14 (5) , 305-314. https://doi.org/10.1054/fipr.2000.0087
    91. Bonno N. Bouma, Joost C.M. Meijers. Role of blood coagulation factor XI in downregulation of fibrinolysis. Current Opinion in Hematology 2000, 7 (5) , 266-272. https://doi.org/10.1097/00062752-200009000-00002
    92. A Reijerkerk, E.E Voest, M.F.B.G Gebbink. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. European Journal of Cancer 2000, 36 (13) , 1695-1705. https://doi.org/10.1016/S0959-8049(00)00157-X
    93. Wei Wang, Mariko Nagashima, Mark Schneider, John Morser, Michael Nesheim. Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation. Journal of Biological Chemistry 2000, 275 (30) , 22942-22947. https://doi.org/10.1074/jbc.M001760200
    94. Mariko Nagashima, Matthias Werner, Manping Wang, Lei Zhao, David R Light, Rene Pagila, John Morser, Peter Verhallen. An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis Model. Thrombosis Research 2000, 98 (4) , 333-342. https://doi.org/10.1016/S0049-3848(00)00184-5
    95. Pauline F. Marx, Tilman M. Hackeng, Philip E. Dawson, John H. Griffin, Joost C.M. Meijers, Bonno N. Bouma. Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage. Journal of Biological Chemistry 2000, 275 (17) , 12410-12415. https://doi.org/10.1074/jbc.275.17.12410
    96. Michael B. Boffa, Robert Bell, Willem K. Stevens, Michael E. Nesheim. Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry 2000, 275 (17) , 12868-12878. https://doi.org/10.1074/jbc.275.17.12868
    97. D.C. Rijken, D.V. Sakharov. Molecular transport during fibrin clot lysis. Fibrinolysis and Proteolysis 2000, 14 (2-3) , 98-113. https://doi.org/10.1054/fipr.2000.0072
    98. Katinka A Schatteman, Filip J Goossens, Simon S Scharpé, Dirk F Hendriks. Proteolytic activation of purified human procarboxypeptidase U. Clinica Chimica Acta 2000, 292 (1-2) , 25-40. https://doi.org/10.1016/S0009-8981(99)00205-3
    99. Florence Dalle Ore, El Hassan Ajandouz, Thierry Giardina, Antoine Puigserver. The membrane-bound basic carboxypeptidase from hog intestinal mucosa1Enzymes: carboxypeptidase B (EC 3.4.17.2); carboxypeptidase D (EC 3.4.17.-); carboxypeptidase H (EC 3.4.17.10); carboxypeptidase M (EC 3.4.17.12); carboxypeptidase N (EC 3.4.17.3).1. Biochimica et Biophysica Acta (BBA) - Biomembranes 1999, 1421 (2) , 234-248. https://doi.org/10.1016/S0005-2736(99)00122-4
    100. M.E. Nesheim. TAFI. Fibrinolysis and Proteolysis 1999, 13 (2) , 72-77. https://doi.org/10.1016/S0268-9499(99)90082-6
    Load all citations